article thumbnail

New CRISPR-Based Tool Called PASTE Gene Editing Inserts Large DNA Sequences at Desired Sites

XTalks

Expanding upon the CRISPR-Cas9 gene editing system, researchers at MIT have designed a new technique called PASTE gene editing that can cut out defective genes and replace them with new genes in a safer and more efficient way. The PASTE gene editing technique was recently published in Nature Biotechnology.

article thumbnail

Key Trends in the Life Sciences to Look Forward to in 2022

XTalks

If the past year is anything to go by, then 2022 will also be a year marked by continued innovations in the life sciences. Here is a look at some life science trends to expect in the coming year, including key themes and topics in the pharmaceutical, biotechnology and medical device industries to keep an eye out for in 2022.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

World AIDS Day 2023: New and Promising Treatments for HIV/AIDS

XTalks

Over 26 weeks of Sunlenca combined with other antiretroviral drugs, 81 percent of participants achieved HIV RNA suppression, reaching levels low enough to be considered undetectable. These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV. percent in the placebo group.

article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. CellProthera also appointed the Newcastle Centre for Life’s GMP cell therapy centre to produce the ATMP.”

Drugs 75
article thumbnail

Gilead and Vir collaborate; Tessera scores $230M; Teladoc & Dexcom bring CGM Tech; Verve unveils lead candidate

Delveinsight

Altitude Life Science Ventures, and the second SoftBank Vision Fund, with participation from the Qatari Investment Authority and other undisclosed investors. Verve Therapeutics has an aim to bring one-and-done gene editing treatments to heart disease. The round was led by Alaska Permanent Fund Corp.,

article thumbnail

Generating Over a Billion Cells with CRISPR for Next Generation Cell Therapies

XTalks

Now a common gene editing tool, the popularity of the CRISPR-Cas9 system has increased over the past decade. CRISPR is notable for engineering living cells, allowing scientists to edit, turn off, delete, or replace genes in a cell’s genome. Harnessing the Cellular Engineering Potential of CRISPR.

article thumbnail

CRISPR breakthroughs: New solutions for common diseases

Drug Discovery World

CRISPR diagnostics have successfully detected various pathogens, including RNA viruses (eg. In the context of non- infectious diseases, CRISPR diagnostics have been developed to detect RNA species, such as human CXCL9 mRNA, for kidney transplant rejection. parvovirus B19, Flaviviridae, Ebola, and Coronaviridae), DNA viruses (e.g.,

DNA 98